Featured Research

from universities, journals, and other organizations

USC Scientists Link Variations In Growth-factor Gene To Risk Of Prostate Cancer

Date:
January 18, 2006
Source:
University of Southern California
Summary:
Two variations in the gene for insulin-like growth factor I are linked to an increased risk of prostate cancer, according to research performed by scientists from the Keck School of Medicine of the University of Southern California, the Broad Institute of Harvard and MIT, and the University of Hawaii.

Two variations in the gene for insulin-like growth factor I (IGF-1) are linked to an increased risk of prostate cancer, according to research performed by scientists from the Keck School of Medicine of the University of Southern California, the Broad Institute of Harvard and MIT, and the University of Hawaii.

"Our results suggest that inherited variation in IGF1 may play a role in prostate cancer risk," write the researchers in a paper published in the January 18, 2006, issue of the Journal of the National Cancer Institute.

USC scientists on this research team included: Iona Cheng, who was first author on the paper; Daniel Stram, Ph.D., professor of preventive medicine at the Keck School and the USC/Norris Comprehensive Cancer Center; Malcolm Pike, Ph.D., professor preventive medicine at the Keck School and USC/Norris; and Keck School of Medicine Dean Brian E. Henderson, M.D., who is also a distinguished professor in preventive medicine and neurology and the Kenneth T. Norris Jr. Chair in Cancer Prevention.

Cheng and her colleagues were able to tease out the relevant gene variations using data from the large Multiethnic Cohort study, for which Henderson is co-principal investigator. This population-based cohort study has collected data on more than 215,000 men and women from Los Angeles and Hawaii over the past decade.

From this cohort and information from cancer registries in California and Hawaii, the scientists were able to identify 2320 men who had developed prostate cancer and match them with 2290 men who did not have a prostate cancer diagnosis. This large population, the study's authors noted, provided "substantial [statistical] power to detect modest genetic effects."

The team knew that high circulating levels of IGF-1 had been linked by previous studies to an increase in prostate cancer risk, and so they focused on that gene and its single-nucleotide polymorphisms (SNPs): tiny point variations in the DNA code for a particular gene. What they found was that several SNPs across the gene were linked to an increased risk of prostate cancer, and two particular SNPs were identified that could account for the genetic associations they observed. Ten percent of the prostate cancer cases in this study could be explained by the variation in DNA sequence of these two polymorphisms.

Because of the ethnic diversity in the cohort's population--included in the group are African Americans, Hawaiians, Japanese Americans, Latinos and whites--the researchers were also able to look at the risk associated with the two SNPs across the five different ethnic groups. As it turned out, the increase in risk was the same throughout all the sub-groups, "suggesting that the inherited variation in IFG1 behaves similarly among ancestral groups and shares an overall biologic effect," the researchers observed.

"Our study critically evaluates the possibility of false positive results, and important issue faced by genetic association studies, and provides strong support for the involvement of the IGF pathway in the development of prostate cancer," Cheng noted. "By identifying the mechanisms in which inherited differences in IGF1 influence disease, we will further advance our understanding of prostate cancer biology and disease susceptibility."

###

Iona Cheng, Daniel O. Stram, Kathryn L. Penney, Malcolm Pike, Loic Le Marchand, Laurence N. Kolonel, Joel Hirschhorn, David Altshuler, Brian E. Henderson, Matthew L. Freedman, "Common Genetic Variation in IGF-1 and Prostate Cancer Risk in the Multiethnic Cohort." Journal of the National Cancer Institute, Vol. 98, No. 2, January 18, 2006.


Story Source:

The above story is based on materials provided by University of Southern California. Note: Materials may be edited for content and length.


Cite This Page:

University of Southern California. "USC Scientists Link Variations In Growth-factor Gene To Risk Of Prostate Cancer." ScienceDaily. ScienceDaily, 18 January 2006. <www.sciencedaily.com/releases/2006/01/060118083049.htm>.
University of Southern California. (2006, January 18). USC Scientists Link Variations In Growth-factor Gene To Risk Of Prostate Cancer. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2006/01/060118083049.htm
University of Southern California. "USC Scientists Link Variations In Growth-factor Gene To Risk Of Prostate Cancer." ScienceDaily. www.sciencedaily.com/releases/2006/01/060118083049.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins